Statement of Comprehensive Income
Difficulty: Beginner
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Pfizer Inc., Consolidated Statement of Comprehensive Income
USD $ in millions
| 12 months ended | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income before allocation to noncontrolling interests | 21,355 | 7,246 | 6,986 | 9,168 | 22,072 | ||||||
| Foreign currency translation adjustments | 1,493 | (800) | (3,200) | (2,096) | (502) | ||||||
| Derivative financial instruments | (378) | (73) | (96) | 438 | 240 | ||||||
| Available-for-sale securities | 532 | 96 | (5) | (372) | (86) | ||||||
| Actuarial gains (losses) | 211 | (740) | 921 | (2,432) | 2,887 | ||||||
| Prior service (costs) credits and other | (128) | (1) | 148 | 420 | 54 | ||||||
| Benefit plans | 83 | (741) | 1,069 | (2,012) | 2,941 | ||||||
| Other comprehensive income (loss) before allocation to noncontrolling interests | 1,730 | (1,518) | (2,232) | (4,042) | 2,593 | ||||||
| Comprehensive income before allocation to noncontrolling interests | 23,085 | 5,728 | 4,754 | 5,126 | 24,665 | ||||||
| Comprehensive (income) loss attributable to noncontrolling interests | (62) | (27) | 1 | (36) | (7) | ||||||
| Comprehensive income attributable to Pfizer Inc. | 23,023 | 5,701 | 4,755 | 5,090 | 24,658 |
| Item | Description | The company |
|---|---|---|
| Foreign currency translation adjustments | Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity. | Pfizer Inc.'s foreign currency translation adjustments increased from 2015 to 2016 and from 2016 to 2017. |
| Derivative financial instruments | Net of tax effect change in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges, after taxes, that is attributable to the parent entity. A cash flow hedge is a hedge of the exposure to variability in the cash flows of a recognized asset or liability or a forecasted transaction that is attributable to a particular risk. The change includes an entity's share of an equity investee's increase (decrease) in deferred hedging gains or losses. | Pfizer Inc.'s derivative financial instruments increased from 2015 to 2016 but then declined significantly from 2016 to 2017. |
| Available-for-sale securities | Gross appreciation or the gross loss in value of the total unsold securities at the end of an accounting period, after tax, attributable to the parent entity. | Pfizer Inc.'s available-for-sale securities increased from 2015 to 2016 and from 2016 to 2017. |
| Benefit plans | Net changes to accumulated comprehensive income during the period related to benefit plans, after tax, attributable to the parent entity. | Pfizer Inc.'s benefit plans declined from 2015 to 2016 but then slightly increased from 2016 to 2017. |
| Comprehensive income attributable to Pfizer Inc. | The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. | Pfizer Inc.'s comprehensive income attributable to Pfizer Inc. increased from 2015 to 2016 and from 2016 to 2017. |